ENTRESTO US RELAUNCH: Heart failure (HF)

After the launch of ENTRESTO, we had a question: why wasn't our market research success translating to actual success? Turns out doctors understood how good our drug was, but we didn't understand them. HF patients have multiple comorbidities. Maintaining stability on 6 or 7 medications is more important to doctors than the merits of any one drug. Our relaunch focused on when to prescribe ENTRESTO, instead of why. Today it's a blockbuster. I'm not saying we deserve all the credit (I'm definitely implying it, though).